UCB SA (UCB-BT)

QUOTE AND NEWS
TheStreet.com  Dec 17  Comment 
BRUSSELS ( The Deal) -- Belgium's UCB is putting Kremers Urban Pharmaceuticals back on the auction block after the collapse of the agreed $1.53 billion sale of the Princeton, N.J.-based generics business to Advent International and Avista Capital...
FiercePharma  Dec 17  Comment 
Weeks after Belgium's UCB announced that it would sell its U.S. generic drug business for $1.53 billion, the company is calling off the sale in light of regulatory pushback over one of the unit's products.
MedPage Today  Dec 9  Comment 
(MedPage Today) -- Whether brivaracetam improves on its parent remains to be seen.
Financial Times  Nov 7  Comment 
Generics sale highlights growth of ‘precision M&A’
TheStreet.com  Nov 7  Comment 
Belgian drugmaker UCB SA announced an agreement Friday, Nov. 7, to sell Princeton, N.J.-based generics maker Kremers Urban Pharmaceuticals Inc. to buyout shops Advent International Corp. and Avista Capital Partners for $1.53 billion. The deal...
FiercePharma  Nov 7  Comment 
Amid the pharma's slimdown craze, Belgium's UCB is getting in on the action by selling its U.S. generic drug unit for $1.53 billion.
Reuters  Oct 22  Comment 
A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc,...
Benzinga  Oct 22  Comment 
IMS Health (NYSE: IMS) today announced that it has entered into an innovative collaboration with UCB to help deliver greater business insights and improved operations, leveraging IMS Health's Nexxus™ Commercial Application Suite and the IMS...
StreetInsider.com  Sep 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Amgen+%28AMGN%29%2C+UCB+Present+Data+from+Romosozumab+Phase+2+in+Postmenopausal+Women+with+Low+BMD/9832979.html for the full story.





You may also be interested in articles related to UCB SA (UCB-BT):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki